GI Dynamics, Inc., a medical device company, engages in the design and application of devices and disease management solutions for treatment of metabolic diseases. The company offers EndoBarrier, a medical device that is indicated for the treatment of patients with type 2 diabetes and obesity. It serves health care providers, such as hospitals and physicians; and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Symbol: ASX:GID
- CUSIP: N/A
- Web: gidynamics.com/
- 50 Day Moving Avg: A$0.05
- 200 Day Moving Avg: A$0.06
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Net Margins: -6,150.00%
- Return on Equity: -418.09%
- Return on Assets: -161.51%
Frequently Asked Questions for GI Dynamics (ASX:GID)
What is GI Dynamics' stock symbol?
GI Dynamics trades on the ASX under the ticker symbol "GID."
Who are some of GI Dynamics' key competitors?
Some companies that are related to GI Dynamics include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Illumina (ILMN), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Bio-Rad Laboratories (BIO), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Catalent (CTLT), Taro Pharmaceutical Industries (TARO) and Puma Biotechnology (PBYI).
Who are GI Dynamics' key executives?
MarketBeat Community Rating for GI Dynamics (ASX GID)MarketBeat's community ratings are surveys of what our community members think about GI Dynamics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
GI Dynamics' management team includes the folowing people:
- Scott Schorer, President, Chief Executive Officer
- James B. Murphy, Chief Financial Officer, Treasurer, Company Secretary
- Brian Callahan, Executive Vice President - Clinical, Regulatory and Quality, Chief Compliance Officer
- Karl-Heinz Blohm Ph.D., Vice President - International Sales
- Daniel Jeffrey Moore, Non-Executive Chairman of the Board
- Juliet Thompson, Director
- Timothy Joseph Barberich, Independent Non-Executive Director
- Graham John Bradley, Independent Non-Executive Director
- Anne Jillian Keating, Independent Non-Executive Director
Consensus Ratings for GI Dynamics (ASX:GID) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for GI Dynamics (ASX:GID)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for GI Dynamics (ASX:GID)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for GI Dynamics (ASX:GID)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for GI Dynamics (ASX:GID)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for GI Dynamics (ASX:GID)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for GI Dynamics (ASX:GID)
Latest Headlines for GI Dynamics (ASX:GID)